|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data provide rationale for using MEK or ERK inhibitors in a subset of driver-negative, MAPK/ERK-dependent melanomas harboring truncating MAP3K8 rearrangements.
|
31186280 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, our analysis revealed a drug-resistant mechanism through which overexpression of tyrosine kinases, including SRC, FES, YES1, and BLK, induced MEK-independent ERK activation in melanoma A375 cells.
|
31101498 |
2019 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Design, synthesis and biological evaluation of fused naphthofuro[3,2-c] quinoline-6,7,12-triones and pyrano[3,2-c]quinoline-6,7,8,13-tetraones derivatives as ERK inhibitors with efficacy in BRAF-mutant melanoma.
|
30396063 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting the DRS with inhibitors in melanoma has the potential to not only disrupt the catalytic apparatus of ERK but also its noncatalytic functions, which have significant impacts on spatiotemporal signaling dynamics and cell fate.
|
31190430 |
2019 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Melanoma LRP1 was found to enhance ERK activation, resulting in increased matrix metalloproteinase (MMP)-9 RNA, protein, and secreted activity, a well-known modulator of melanoma metastasis.
|
30458112 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, we found that RGS1 may promote melanoma progression through the downstream effects of Gαs signaling, such as the increased phosphorylation of AKT and ERK by western blotting.
|
29620236 |
2018 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Fourty percent of all melanomas harbor a mutation in the signaling adaptor BRAF (V600E) that results in ERK hyperactivity as an oncogenic driver.
|
29983861 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The p90 ribosomal S6 kinase (RSK), an important ERK effector, activates YB-1 to drive melanoma growth.
|
30356079 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The revealing of mutations in the BRAF/MEK/ERK pathway has led to the development of BRAF inhibitors such as vemurafenib and dabrafenib for the treatment of cutaneous MM.
|
29363351 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hyperactivation of both ERK and AKT pathways was associated with BRAFi resistance in melanoma with wildtype PTEN.
|
29551771 |
2018 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma.
|
29295999 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeted-gene silencing of BRAF to interrupt BRAF/MEK/ERK pathway synergized photothermal therapeutics for melanoma using a novel FA-GNR-siBRAF nanosystem.
|
29684526 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To review the recent advances in elucidating the metabolic effects of BRAF and MEK inhibitors (clinical inhibitors of the MAPK/ERK pathway) in melanoma and discuss the underlying mechanisms involved in the way metabolism can influence melanoma cell death and resistance to BRAF and MEK inhibitors.
|
29413908 |
2018 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A sequential and coordinated activation of ERK, JNK and STAT3 with RACK1 is shown to accelerate aggressive melanoma development in vivo.
|
28343944 |
2017 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma.
|
29050218 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Western blot results for the ERK inhibition in human melanoma SK-MEL-2 cell lines show that I-16 inhibits the proliferation of SK-MEL-2 cell lines without paradoxical activation of ERK, which support the hypothesis that the inhibition of Pan-Raf and RTKs might be a tractable strategy to overcome the resistance of melanoma induced by the therapy with the current selective BRaf<sup>V600E</sup> inhibitors.
|
28485964 |
2017 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, treatment of melanoma cells with ADA reduced nuclear translocation and activation of NF-κB, decreased the expression of the anti-apoptotic proteins c-FLIP, XIAP, and Bcl-2 and inhibited the phosphorylation and activation of both AKT and ERK proteins, two of the most frequently deregulated pathways in melanoma.
|
28289382 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Melanoma specific killing was in the order; ZnO > B4C ≥ Cu > MgO > Co3O4 > Fe2O3 > NiO, ZnO-NP inhibiting B16F10 and A375 cells as well as ERK enzyme (>90%) and several other cancer-associated kinases (AKT, CREB, p70S6K).
|
29377653 |
2017 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Oncogenic mutations of BRAF lead to constitutive ERK activity that supports melanoma cell growth and survival.
|
27813079 |
2017 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We show that BRAF expression is required for ERK activation and nevi development, demonstrating a critical role in the early stages of NRAS-driven melanoma.
|
28497782 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, ERK cascade inhibitors have been proven beneficial almost exclusively for BRAF mutant melanomas.
|
29180761 |
2017 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ERK and AKT are constitutively activated in conjunctival nevi, PAM and melanoma.
|
28938534 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma.
|
28368422 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
AURKA Overexpression Is Driven by FOXM1 and MAPK/ERK Activation in Melanoma Cells Harboring BRAF or NRAS Mutations: Impact on Melanoma Prognosis and Therapy.
|
28188776 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aims to explore the effects of microRNA-21 (miR-21) and ERK/NF-κB signaling pathway on human melanoma A375 cells.
|
27533779 |
2017 |